Revolution Medicines (NASDAQ:RVMD) used its fourth-quarter and full-year 2025 earnings call to highlight progress across its RAS(ON) inhibitor pipeline, with management emphasizing multiple ongoing an ...
This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results